Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)
  7. Department of Pathology and Laboratory Medicine (416)
  8. Gastrointestinal Oncology Service (387)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Smoking history and response to nivolumab in patients with advanced NSCLCS
    Meeting Abstract

    Hellmann, M. D.; Creelan, B. C.; Woo, K.; Sima, C. S.; Iams, W. T.; Antonia, S. J.; Horn, L.; Brahmer, J. R.; Gettinger, S.; Harbison, C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC)
    Meeting Abstract

    Hammers, H.; Plimack, E. R.; Infante, J. R.; Ernstoff, M.; Rini, B. I.; McDermott, D. F.; Razak, A.; Pal, S. K.; Voss, M.; Sharma, P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Multi-arm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling
    Meeting Abstract

    Garrido, P.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Barlesi, F.; Arkenau, H.; Lara, P.; Paik, P. K.; Morgensztern, D.; Gadgeel, S.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) and as a single agent for platinum resistant ovarian cancer
    Meeting Abstract

    Garcia, A. A.; Makker, V.; Spitz, D. L.; Matei, D. E.; Nick, A. M.; Landen, C. N.; Alvarez, E. A.; Mendelson, D. S.; Strother, R. M.; Seon, B. K.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Brentuximab vedotin in combination with CHP in patients (pts) with newly-diagnosed CD30+ peripheral T-cell lymphomas (PTCL): 2-year follow-up
    Meeting Abstract

    Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Illidge, T.; Huebner, D.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience)
    Meeting Abstract

    Baselga, J.; Zamagni, C.; Gomez, P.; Bermejo, B.; Nagai, S.; Melichar, B.; Chan, A.; Mangel, L.; Bergh, J.; Costa, F. P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
    Journal Article

    Wang, Z. M.; Zhu, B.; Zhang, M. F.; Parikh, H.; Jia, J. P.; Chung, C. C.; Sampson, J. N.; Hoskins, J. W.; Hutchinson, A.; Burdette, L.; more...
    Human Molecular Genetics (2014)

    Fulltext@MSK | Save
  • Crystal structure, mutational analysis and RNA-dependent ATPase activity of the yeast DEAD-box pre-mRNA splicing factor Prp28
    Journal Article

    Jacewicz, A.; Schwer, B.; Smith, P.; Shuman, S.
    Nucleic Acids Research (2014)

    Fulltext@MSK | Save
  • Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer
    Journal Article

    Peerschke, E. I.; Pessin, M. S.; Maslak, P.
    American Journal of Clinical Pathology (2014)

    Fulltext@MSK | Save